NEW YORK, Sept 26 – Gene Logic (Nasdaq: GLGC) said Tuesday it had reached a deal that would give Amersham Pharmacia Biotech K.K. the exclusive rights to market sell Gene Logic’s products in Japan.
Under the terms of the deal, Amersham Pharmacia Biotech K.K, the Japanese subsidiary of Amersham Pharmacia Biotech, will market and sell Gene Logic’s range of databases and software tools to Japanese pharmaceutical and biotech companies.
Financial terms of the agreement were not disclosed.
“This alliance fits with Amersham Pharmacia Biotech K.K.'s business strategy and will help further strengthen our position in the genomics market in Japan," Kazuo Takeuchi, vice president at Amersham Pharmacia Biotech K.K., said in a statement.
Mark Gessler, president and CEO of Gene Logic, said the deal reflected the company’s efforts to expand its marketing reach overseas.
Amersham Pharmacia Biotech, is the life sciences division of Nycomed Amersham (London: NAM; NYSE: NYE).
Gene Logic, of Gaithersburg, Md., has developed a database that contains information about gene expression in human and animal tissues.
Shares of Gene Logic were down 3/4, or 3.6 percent, at 201/4 in afternoon trading.